LDN stands for low-dose naltrexone
Naltrexone is an opioid antagonist typically used in higher doses to treat alcohol and opioid dependence. However, in lower doses (usually between 1.5 to 4.5 mg), it has been explored for various off-label uses due to its potential immune-modulating and anti-inflammatory effects.
The mechanism of action of LDN is not completely understood, but several hypotheses have been proposed:
1. Endorphin Modulation: LDN is thought to work by temporarily blocking opioid receptors in the brain, which leads to a rebound effect, causing the body to increase its production of endorphins – natural chemicals that modulate the immune system and reduce inflammation.
2. Immune System Modulation: By increasing endorphin levels, LDN may help regulate immune function. Endorphins bind to opioid receptors on immune cells, influencing their activity and potentially reducing autoimmune responses and inflammation.
3. Microglial Modulation: LDN may also affect microglial cells in the central nervous system, leading to reduced inflammation and neuroprotection. This mechanism has been proposed in the context of neurodegenerative diseases such as multiple sclerosis and Parkinson’s disease.
4. Upregulation of Opioid Receptors: LDN has been shown to increase the number and sensitivity of opioid receptors in the body over time. This upregulation could enhance the body’s response to its own endorphins, potentially providing pain relief and other therapeutic benefits.
LDN at low doses appears to exert its effects by modulating the endorphin system, immune function, and inflammation. While more research is needed to fully understand its mechanisms of action, LDN shows promise for various medical conditions, including autoimmune diseases, chronic pain, and certain neurological disorders.
